Oligonucleotide Therapies: The Past and the Present
Top Cited Papers
Open Access
- 1 August 2015
- journal article
- review article
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 26 (8), 475-485
- https://doi.org/10.1089/hum.2015.070
Abstract
In this review we address the development of oligonucleotide (ON) medicines from a historical perspective by listing the landmark discoveries in this field. The various biological processes that have been targeted and the corresponding ON interventions found in the literature are discussed together with brief updates on some of the more recent developments. Most ON therapies act through antisense mechanisms and are directed against various RNA species, as exemplified by gapmers, steric block ONs, antagomirs, small interfering RNAs (siRNAs), micro-RNA mimics, and splice switching ONs. However, ONs binding to Toll-like receptors and those forming aptamers have completely different modes of action. Similar to other novel medicines, the path to success has been lined with numerous failures, where different therapeutic ONs did not stand the test of time. Since the first ON drug was approved for clinical use in 1998, the therapeutic landscape has changed considerably, but many challenges remain until the expectations for this new form of medicine are met. However, there is room for cautious optimism.Keywords
This publication has 138 references indexed in Scilit:
- Functional In Vivo Delivery of Multiplexed Anti-HIV-1 siRNAs via a Chemically Synthesized Aptamer With a Sticky BridgeMolecular Therapy, 2013
- RNA-Based Therapeutics: Current Progress and Future ProspectsCell Chemical Biology, 2012
- Allele-Selective Inhibition of Mutant Huntingtin Expression with Antisense Oligonucleotides Targeting the Expanded CAG RepeatBiochemistry, 2010
- Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decayNature, 2010
- Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancerExperimental and Molecular Pathology, 2009
- Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAsNature Biotechnology, 2009
- Recognition of Chromosomal DNA inside Cells by Locked Nucleic AcidsBiochemistry, 2008
- Antisense Masking of an hnRNP A1/A2 Intronic Splicing Silencer Corrects SMN2 Splicing in Transgenic MiceAmerican Journal of Human Genetics, 2008
- Antisense inhibition at the β-secretase-site of β-amyloid precursor protein reduces cerebral amyloid and acetyl cholinesterase activity in Tg2576Neuroscience, 2007
- Silencing of microRNAs in vivo with ‘antagomirs’Nature, 2005